Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1108693

	registered interest
	date	01/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on the prescription of medicinal cannabis oil for patients with (a) cerebral palsy and (b) arthritis.
	tabling member constituency	Banff and Buchan
	tabling member printed	David Duguid
	uin	239283
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>The Department has not discussed with the National Institute for Health and Care Excellence (NICE) the prescription of medicinal cannabis oil for patients with cerebral palsy and arthritis.</p><p> </p><p>NICE is the independent expert body that develops authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE is developing guidance on the prescribing of cannabis-based medicinal products by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p><p> </p><p>Following a public consultation on the draft scope, the guidance will focus on the use of cannabis-based products in the treatment of chronic pain, intractable nausea and vomiting, spasticity and severe treatment-resistant epilepsy, conditions where the evidence is currently most advanced. A consultation on the draft guidance is expected in the summer.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 09/04/2019 14:41:04 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4606 label Biography information for David Duguid

1109775

	registered interest
	date	04/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will issue a response to Early Day Motion 1832, on legalisation of medical cannabis.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	241057
	answer	answer is ministerial correction date of answer 09/04/2019 answer text <p>The Government is clear that the decision to prescribe a cannabis-based product for medicinal use should only be made where it is clinically appropriate and in the best interest of the patient. This will be subject to local National Health Service governance and funding arrangements for prescribing unlicensed medicines, and patients will not be able to be prescribed such products by their general practitioner – and would require referral to a specialist clinician on the basis of clinical need.</p><p>The evidence base for cannabis-based products for medicinal use is still developing. However, the changes to the law are designed to encourage further research and the National Institute for Health Research has issued two calls for research proposals to rapidly advance knowledge in this area and remains open to research proposals outside of these calls in this priority area.</p><p>Interim clinical guidance, issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists is based on the best available international evidence and reflects clinical guidance that has been published in other jurisdictions. This guidance will be updated and replaced in October 2019 by that commissioned from the National Institute for Health and Care Excellence.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 09/04/2019 14:40:03 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady

1110299

	registered interest
	date	08/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the NICE guidance on prescribing cannabis-based products for medical use will be published.
	tabling member constituency	Liverpool, West Derby
	tabling member printed	Stephen Twigg
	uin	241989
	answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is due to publish its guidelines on cannabis-based products for medicinal use in October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:58:48 answering member 4455 label Biography information for Seema Kennedy
	tabling member	167 label Biography information for Stephen Twigg

1110302

	registered interest
	date	08/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of NHS prescriptions for medical cannabis issued in each month since 1 November 2018.
	tabling member constituency	Liverpool, West Derby
	tabling member printed	Stephen Twigg
	uin	241990
	answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p> </p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from November 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p> </p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from November 2018 to January 2019:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>November 2018</p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>46</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>175</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p> </p><p>Data from the NHS Business Services Authority for between November 2018 and January 2019 shows that no prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. We expect data for February 2019 to be available shortly.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p><p>94 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.</p><p> </p><p>Intelligence from NHS England Controlled Drugs Accountable Officers is that, up until the end to March 2019, one private prescription has been issued for a cannabis-based product for medicinal use in secondary/tertiary care in England.</p><p> </p><p>Import notifications to the Medicines and Healthcare products Regulatory Agency indicate a greater number of supplies. We are therefore cross-checking to ensure that information on the number of prescriptions for cannabis-based products for medicinal use aligns across the different data sources.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:56:59 answering member 4455 label Biography information for Seema Kennedy
	tabling member	167 label Biography information for Stephen Twigg

1111101

	registered interest
	date	10/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS prescriptions for medicine in which THC is the dominant ingredient.
	tabling member constituency	Newcastle-under-Lyme
	tabling member printed	Paul Farrelly
	uin	243361
	answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Department has made no estimate of the number of National Health Service prescriptions for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the NHS and independent sector.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 11:49:19 answering member 4455 label Biography information for Seema Kennedy previous answer version 114110 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
	tabling member	1436 label Biography information for Paul Farrelly

1111106

	registered interest
	date	10/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what advice has been issued to Clinical Commissioning Groups on the criteria for the prescription of medicinal cannabis.
	tabling member constituency	Leigh
	tabling member printed	Jo Platt
	uin	243575
	answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Chief Medical Officer and NHS England issued a letter on the 31 October 2018, and a supplementary letter on 20 November 2018, providing guidance to clinicians, the National Health Service and independent organisations following the rescheduling of cannabis-based products for medicinal use on 1 November 2018. This signposts interim guidance issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists.</p><p> </p><p>Furthermore, the National Institute for Health and Care Excellence (NICE), has been commissioned to develop guidelines on the prescribing of cannabis-based medicinal products by October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines. This guidance will update and replace the interim guidance.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:26:52 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4673 label Biography information for Jo Platt

1121479

	registered interest
	date	11/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis (a) THC and (b) CBD have been issued in England since December 2018.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	244142
	answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from December 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from December 2018 to January 2019:</p><table><tbody><tr><td><p> </p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 24/04/2019 13:15:40 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1123157

	registered interest
	date	25/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patient and health professional organisations are engaged in the Department's working group on medicinal cannabis.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Tom Brake
	uin	247543
	answer	answer is ministerial correction date of answer 03/05/2019 answer text <p>The Department has held a number of engagement events with representatives of patients and health professionals in relation to this policy.</p><p>The Department has also arranged three meetings with stakeholders, ahead of the National Institute for Health and Care Excellence publishing its guidelines on the prescribing of cannabis-based products for medicinal use in October 2019. These meetings are attended by relevant Government departments, public bodies including advisory committees and professional clinical organisations. The purpose of these meetings is to make sure work, already commissioned to implement policy on medicinal cannabis, continues to align in the interim period before the guidelines are issued.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 03/05/2019 13:02:14 answering member 4455 label Biography information for Seema Kennedy
	tabling member	151 label Biography information for Tom Brake

1123443

	registered interest
	date	26/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	247998
	answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 247999 question first answered 07/05/2019 16:43:13 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning